PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP ) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"). Nikhil Lalwani, President and CEO of ANI, stated, "Today marks a major milestone in our strategy to expand our Rare Disease business and deliver on our purpose of 'Serving Patients, Improving Lives.' Alimera is highly synergistic to our Rare Disease business, and we believe our proven commercial execution capabilities can further unlock the value of ILUVIEN and YUTIQ, two growing and durable assets, as well as accelerate the growth of Cortrophin Gel in ophthalmology.